the aid library

LIST OPTIONS

Filter

1288

Sort by:

Direction:

Download (159)

View PDF (261)

Planetary Health Ethics: Beyond First Principles

FosterA.; J. Cole A. Farlow and I. Petrikova (2019) CC

Planetary health is a transdisciplinary approach that aims to advance the understanding of the links between human-driven changes to the planet and their consequences, and to develop appropriate solutions to the challenges identified. This emerging movement has not yet agreed upon a code of ethics t... more

Download (209)

View PDF (295)

Global Health Education Competencies Tool-Kit

Astle. B.; C.A.Faerron-Guzman; A. Landry, et al. Consortium for Universities for Global Health (2018) CC

2nd edition. The tool kit provides learning objects and curricular content to support the competencies for those proficiency/trainee levels

Download (854)

View PDF (1300)

Global report on psoriasis

World Health Organization WHO (2016) C_WHO

Psoriasis, which can involve the skin, nails and joints, is a chronic, painful, disfiguring and disabling noncommunicable disease (NCD) for which there is no cure. It negatively impacts on quality of life. Some of those who suffer from the disease develop chronic, inflammatory arthritis (psoriatic a... more

Download (129)

View PDF (1006)

Germanys expanding role in global health

Ilona Kickbusch, Christian Franz, Anna Holzscheiter, Iris Hunger, Albrecht Jahn, Carsten Kö; hler, Oliver Razum, Jean-Olivier Schmidt Lancet 2017; 390: 898– 912 (2017) CC

Germany has become a visible actor in global health in the past 10 years. In this Series paper, we describe how this development complements a broad change in perspective in German foreign policy.

Download (135)

View PDF (240)

Health of older refugees and migrants

World Health Organization WHO, Regional Office for Europe (2018) C_WHO

Technical guidance. This technical guidance aims to inform policy and practice development specifically related to improving the health of older refugees and migrants within the European Union and the larger WHO European Region. Both ageing and migration are in themselves complex multidimensional p... more

Download (162)

View PDF (242)

World Report on Vision

World Health Organization WHO (2019) C_WHO

At present at least 2.2 billion people around the world have a vision impairment, of whom at least 1 billion have a vision impairment that could have been prevented or is yet to be addressed. The world faces considerable challenges in terms of eye care, including inequalities in the coverage and qua... more

Download (1883)

View PDF (1398)

Ebola Virus Disease in Africa: Epidemiology and health facility related transmission

Shears, Paul, T.J.D. O'Dempsey (2015)

A review of current literature and up date data from the field, April 2015. This report has been published in part in J Hosp Inf. 2015;90:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=ebola+nosocomial+shears

Download (262)

View PDF (165)

Global Antimicrobial Resistance Surveillance System (GLASS): Molecular methods

World Health Organization WHO (2019) C_WHO

Molecular methods for antimicrobial resistance (AMR)diagnostics to enhance the Global Antimicrobial Resistance Surveillance System

Download (202)

View PDF (194)

Antibiotic resistance: using a cultural contexts of health approach to address a global health challenge

Ledingham, K. World Health Organization Europe (2020) C_WHO

This policy brief has been developed in response to the contemporary challenge of antibiotic resistance (‎ABR)‎. ABR poses a formidable threat to global health and sustainable development. It is now increasingly recognized that the systematic neglect of cultural factors is one of the biggest obs... more

Download (127)

View PDF (170)

Survey Tool and Guidance: Rapid, simple, flexible behavioural insights on COVID-19

World Health Organization WHO (2020) C_WHO

This document provides guidance to Member States in the WHO European Region that wish to conduct behavioural insights studies related to COVID-19. Studies can be used to monitor public knowledge, risk perceptions, behaviours and trust with the overall aim to inform national COVID-19 outbreak respons... more

Download (60)

View PDF (712)

Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study

Karagiannidis, C.; et al. (2020) C1

DOI:https://doi.org/10.1016/S2213-2600(20)30316-7 The Lancet Respiratory Medicine

Download (99)

View PDF (120)

Corticosteroids for COVID-19

World Health Organization WHO (2020) C_WHO

WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19. We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ... more

Download (103)

View PDF (119)

WHO Living guideline: Drugs to prevent COVID-19
recommended

World Health Organization WHO (2021) C_WHO

Interim guidance 2 march 2021 Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform... more

Download (107)

View PDF (153)

Preventing and mitigating COVID-19 at work

World Health Organization WHO (2021) C_WHO

Workplaces outside of healthcare facilities can be also settings for transmission of COVID-19. Outbreaks of COVID-19 has been reported in various types of workplaces and job categories. All workers should be protected from acquiring COVID-19 because of their work. The prevention of COVID-19 in ... more

Download (123)

View PDF (154)

Cardiac Rehabilitation Change Package

Centers for Disease Control and Prevention (CDC) (2018) CC

This Cardiac Rehabilitation Change Package was completed by the Centers for Disease Control and Prevention (CDC) in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) with the purpose of helping cardiac rehabilitation programs, hospital quality improv... more

Download (131)

View PDF (179)

Global Status Report on Road Safety

World Health Organisation (WHO) (2018) C_WHO

Road safety is an issue that does not receive anywhere near the attention it deserves – and it really is one of our great opportunities to save lives around the world

Download (78)

View PDF (946)

Air pollution and diabetes: it's time to get active!

O'Donovan, G.; Cadena-Gaitán, C. (2018) CC

Cardiovascular disease, diabetes, chronic obstructive pulmonary disease, cancers, and other non-communicable diseases are among the leading causes of morbidity and mortality in low-income, middle-income, and high-income countries, and The Lancet Taskforce recently made the case for investing in non-... more

Download (112)

View PDF (580)

Visceral leishmaniasis: a global overview

Wamai, R.; Khan, J.; McGloin, J.; Ziaggi, G. Jornal of Global Health Science (2020) CC

A group of enzootic and zoonotic protozoan infections, the leishmaniases constitute among the most severely neglected tropical diseases (NTDs) and are found in all continents except Oceania. Representing the most common infectious diseases, NTDs comprise an open-ended list of some 20 parasitic, bact... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (24)

View PDF (23)

World Heart Federation Roadmap for Heart Failure

Ferreira, J.P.; Kraus, S.; Mitchell, S. et al. Global Heart (2019) CC

In 2012, all Member States of the World Health Organization (WHO) endorsed a historical target to reduce premature mortality from noncommunicable diseases (NCD). This commitment was echoed in 2015 by the United Nations Sustainable Development Goals, which included a target to reduce premature morta... more

WHO Living guideline: Drugs to prevent COVID-19 recommended

WHO Living guideline: Drugs to prevent COVID-19
recommended